ELDN Stock — Eledon Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$2.62

Market cap

$212.9M

Cash

$88.8M

Enterprise value

$124.1M

Balance sheet

Cash	$88.8M
Debt	$0.0M
Net cash	$88.8M
Enterprise value	$124.1M
Basic shares	80.9M shares
Fully diluted shares	119.8M shares
Fully diluted market cap	$313.9M
Cash per share	$1.10

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ELDN daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 12 - Mar 26	AT-1501	Phase 1/2	Prevention of Rejection in Kidney Transplant	—
Jan 12 - Feb 23	AT-1501	Phase 2	Kidney Transplant Rejection	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

tegoprubart

Phase 2 · Active Modality: antibody

Target CD40L (CD40 ligand)

Partnerships eGenesis, Inc. (non-exclusive collaborative research agreement, Jan 2023: access to tegoprubart for preclinical and clinical xenotransplantation studies in eGenesis kidney, heart and islet cell programs)

Indications

kidney transplant rejection prevention (tacrolimus replacement) (Phase 2)
pancreatic islet cell transplantation (type 1 diabetes) (Stage not disclosed)
xenotransplantation (Stage not disclosed)

Status note Anti-CD40L antibody. Kidney transplant: Phase 2 BESTOW trial (IND cleared July 2022; topline 12-month data announced November 6, 2025; company believes results if replicated in Phase 3 would support approvability) running in parallel with ongoing Phase 1b trial (first subject dosed July 2022; 24-month long-term extension data presented January 2026). Orphan drug designation 2022 for prevention of allograft rejection in pancreatic islet cell transplantation.

ALS program

Preclinical · Active

Target CD40L

Partnerships ALS Therapy Development Institute (exclusive patent/know-how license, May 2015)

Indications

amyotrophic lateral sclerosis (ALS) (Preclinical)

Status note Program milestones under the ALS TDI Agreement include dosing first subjects in a first NHP toxicity study and dosing the first patient in a Phase 1 trial. No named candidate disclosed.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	AT-1501
Lead indication	Kidney Transplant Rejection
Lead phase	Phase 2
Active trials	2
Collaborator trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06126380	Phase 2	Enrolling by invitation	Sponsor	Eledon Pharmaceuticals	—	Kidney Transplant Rejection	—
NCT05027906	Phase 1/2	Recruiting	Sponsor	Eledon Pharmaceuticals	—	Prevention of Rejection in Kidney Transplant	—
NCT06305286	Phase 1/2	Active, not recruiting	Collaborator	University of Chicago	—	Type 1 Diabetes Mellitus	—
NCT06972069	Early Phase 1	Recruiting	Collaborator	Tatsuo Kawai, MD, PhD	—	Kidney Failure; Transplant Recipient (Kidney); Transplant Tolerance	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Eledon Pharmaceuticals on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Sphera Biotech	1,191,187	-580,944	0.67%	2026-08-14
ADAR1 Capital Management	647,812	-326,609	0.12%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ELDN — Eledon Pharmaceuticals Inc.